Synthesis and evaluation of two technetium-99m-labeled peptidic 2-nitroimidazoles for imaging hypoxia.
The presence of hypoxic cells in solid tumors is a marker for therapy-resistant, aggressive disease. The noninvasive detection of hypoxic cells in tumors by radiolabeled 2-nitroimidazoles is a diagnostic technique under current evaluation. Two peptidic agents, dimethylglycyl-L-seryl-L-cysteinyl-lysyl{N(epsilon)-[1-(2-nitro-1H -im idazolyl)acetamido]}glycine (RP435) and dimethylglycyl-tert-butylglycyl-L-cysteinyl-glycine-[2-(2-ni tro-1H-im idazolyl)ethyl]amide (RP535) have been synthesized. Both agents contain an N(3)S class chelator for (99m)Tc and Re and a 2-nitroimidazole group which can be enzymatically reduced and selectively trapped in cells under hypoxic conditions. Two isomers of (99m)TcO-RP435, which are assumed to be syn and anti conformations, were observed on HPLC analysis. The interconversion of the two isomers in aqueous solution was investigated. In contrast, RP535 chelated (99m)Tc to form a single isomer and no conversion to its counterpart has been observed on HPLC analysis. The tert-butyl group on the chelator may inhibit the formation and interconversion of the syn and anti isomers of (99m)TcO-RP535. Both tracers showed a significant degree of hypoxia-specific accumulation in an in vitro assay, with (99m)TcO-RP535 showing higher selectivity for hypoxic cells than (99m)TcO-RP435. These results suggest that (99m)TcO-RP535 represents a lead compound worthy of further investigation as an agent for imaging hypoxia in tumors.
Su
Z F
ZF
Department of Medical Biophysics, University of Toronto, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada.
Zhang
X
X
Ballinger
J R
JR
Rauth
A M
AM
Pollak
A
A
Thornback
J R
JR
D000818:Animals; D016466:CHO Cells / Q000378:metabolism; D015687:Cell Hypoxia; D002614:Chelating Agents / Q000138:chemical synthesis; D002851:Chromatography, High Pressure Liquid; D006224:Cricetinae; D004355:Drug Stability; D008024:Ligands; D009593:Nitroimidazoles / Q000138:chemical synthesis* / Q000737:chemistry; D009795:Octanes / Q000737:chemistry; D009842:Oligopeptides / Q000138:chemical synthesis* / Q000493:pharmacokinetics; D015609:Organotechnetium Compounds / Q000138:chemical synthesis* / Q000493:pharmacokinetics; D010455:Peptides / Q000138:chemical synthesis* / Q000737:chemistry; D019275:Radiopharmaceuticals / Q000138:chemical synthesis* / Q000493:pharmacokinetics; D012995:Solubility; D013237:Stereoisomerism; D014867:Water / Q000737:chemistry
D002614:Chelating Agents; D008024:Ligands; D009593:Nitroimidazoles; D009795:Octanes; D009842:Oligopeptides; D015609:Organotechnetium Compounds; D010455:Peptides; C400062:RP 435; C400061:RP 455; D019275:Radiopharmaceuticals; C400064:oxotechnetium-RP 435; C400063:oxotechnetium-RP 455; D014867:Water